{"id":"W1988878042","doi":"10.1158/1078-0432.ccr-14-1814","title":"A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors","year":2014,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":326,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Trametinib; Internal medicine; Adverse effect; Stomatitis; MEK inhibitor; Rash; KRAS; Gastroenterology; Cancer; Oncology; Colorectal cancer; Kinase; MAPK/ERK pathway","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001878069,0.00204731,0.002210865,0.0006500231,0.0005201902,0.001005205,0.001022151,0.0011269,0.003241941],"category_scores_gemma":[0.0009415887,0.0009107001,0.001743841,0.0006317734,0.001350111,0.001161164,0.0004262615,0.004641777,0.0008796896],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00124461,"about_ca_system_score_gemma":0.001647921,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007563183,"about_ca_topic_score_gemma":0.001927003,"domain_scores_codex":[0.9993522,0.0003000277,0.0000362382,0.0001208437,0.00006515571,0.0001255673],"domain_scores_gemma":[0.9991315,0.000126056,0.0001930803,0.0001048359,0.00004900749,0.0003956611],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6380624,0.2103003,0.006352157,0.0008078515,0.001320225,0.0002635924,0.0004460605,0.003442099,0.05684829,0.0002659256,0.002570093,0.07932109],"study_design_scores_gemma":[0.4525857,0.5326717,0.008105381,0.00002228006,0.0003414439,0.0001918872,0.00005003505,0.00108821,0.003699204,0.0001416337,0.001079438,0.00002307398],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950158,0.0007591046,0.0005074607,0.000204425,0.00007080867,0.001992521,0.0004583141,0.00007574388,0.000915854],"genre_scores_gemma":[0.9931271,0.0007492466,0.001441984,0.0004314975,0.0001039609,0.001853411,0.001107075,0.00002444733,0.001161256],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003241941,"threshold_uncertainty_score":0.0108453,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04835023933742931,"score_gpt":0.4285802565226542,"score_spread":0.3802300171852249,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}